第53回日本免疫学会学術集会

^○Tatsuya Hasegawa^1,2,3, Tomonori Oka^2,3, Heehwa G. Son^2,3, Valeria S. Oliver-Garcia^2,3, Marjan Azin^2,3, Thomas M. Eisenhaure⁴, David J. Lieb⁴, Nir Hacohen^2,4, Shadmehr Demehri^2,3 (1.MIRAI Technology Institute, Shiseido Co., Ltd., 2.Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, 3.Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, 4.Broad Institute of MIT and Harvard)

^○Daiki Takewaki^1,2, Yuya Kiguchi^2,3, Hiroaki Masuoka², Mallahalli Manu¹, Ben J E Raveney¹, Seiko Narushima⁴, Rina Kurokawa², Yusuke Ogata², Sachiko Miyake⁵, Wakiro Sato¹, Wataru Suda², Takashi Yamamura¹ (1.Department of Immunology, National Center of Neurology and Psychiatry, 2.Laboratory for Symbiotic Microbiome Sciences, RIKEN Center for Integrative Medical Sciences, 3.Department of Computational Biology and Medical Sciences, The University of Tokyo, 4.Laboratory for Mucosal Immunity, RIKEN Center for Integrative Medical Sciences, 5.Department of Immunology, Juntendo University)

^○Koichiro Suzuki¹, Takahiro Yamada^1,2, Yusuke Kinashi¹, Seiga Komiyama¹, Yuyo Ka³, Kayo Tomiyama³, Nanako Ushio-Watanabe⁴, Yoshifumi Nishikawa⁴, Koji Hase¹ (1.Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Science, Keio University, 2.Department of Immunobiology, Yale School of Medicine, 3.Central Institute for Experimental Medicine and Life Science (CIEM), 4.National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine)

^○Mitsuru Arase¹, Mari Murakami^1,2, Kiyoshi Takeda^1,2 (1.Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, 2.WPI Immunology Frontier Research Center, Osaka University)

^○Daichi Mori¹, Yoshiyuki Goto^1,2,3,4 (1.Project for Host Microbial interactions in Symbiosis and Pathogenesis, Division of Molecular Immunology, Medical Mycology Research Center, Chiba university, 2.Division of Pandemic and Post-disaster Infectious Diseases, Research Institute of Disaster Medicine, Chiba University, Chiba, 3.Division of Infectious Disease Vaccine R&D, Research Institute of Disaster Medicine, Chiba University, Chiba, 4.Chiba University, Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba)

^○Keishu Takahashi¹, Naoki Morita¹, Ryutaro Tamano¹, Peng Gao¹, Noriho Iida², Akira Andoh³, Hirotsugu Imaeda⁴, Ken Kurokawa⁵, Mayo Tsuboi⁵, Yoku Hayakawa⁵, Mitsuhiro Fujishiro⁵, Reiko Shinkura¹ (1.Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo, 2.Department of Gastroenterology, Graduate School of Medical Sciences, Kanazawa University, 3.Department of Medicine, Shiga University of Medical Science, 4.Department of Gastroenterology, Nagahama City Hospital, 5.Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo)

^○Yoshihiro Ito¹, Keitaro Fukuda^1,2, Michiko Koizumi-Kitajima¹, Masayuki Amagai^1,2 (1.Keio University, School of Medicine, Department of Dermatology, 2.Laboratory for Skin Homeostasis, IMS, RIKEN)

^○Satoshi Koga¹, Kazuyo Moro^1,2,3 (1.Laboratory for Innate Immune Systems, Graduate School of Medicine, Osaka University, 2.Laboratory for Innate Immune Systems, RIKEN-IMS, 3.Laboratory for Innate Immune Systems, iFReC, Osaka University)